Document Detail


Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
MedLine Citation:
PMID:  15229389     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare the oral antiplatelets, phosphodiesterase III inhibitor cilostazol and the thienopyridine ticlopidine, for one-month effectiveness and safety as an adjunctive therapy after coronary stenting.
METHODS: Published studies retrieved through Medline and other databases from 1966-2002. Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting. Major adverse cardiac events (MACE), stent-associated thrombosis or adverse side effects after coronary stenting were compared between the two study arms and expressed with the odds ratios (OR) specific for the individual studies and meta-analytic summary for OR.
RESULTS: Five clinical studies met the inclusion criteria, and 4 of these studies underwent meta-analysis. With regard to the comparison of the OR summary for MACE and stent-associated thrombosis for the clinical outcome, there were no statistical significant differences between aspirin plus cilostazol and aspirin plus ticlopidine. While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol.
CONCLUSIONS: Our meta-analysis results indicated that there were no differences between cilostazol (plus aspirin) and ticlopidine (plus aspirin) with regard to effectiveness and safety for a one-month period when used as an adjunctive therapy after coronary stenting.
Authors:
Masayuki Hashiguchi; Keiko Ohno; Rieko Nakazawa; Satoshi Kishino; Mayumi Mochizuki; Tsuyoshi Shiga
Related Documents :
16128779 - Fluoroscopically guided insertion of self-expandable metal esophageal stents for pallia...
18572359 - Long-term results of combined common femoral endarterectomy and iliac stenting/stent gr...
10618299 - Short- and intermediate-term results of (32)p radioactive beta-emitting stent implantat...
2299709 - Primary double pigtail stenting as a treatment of upper urinary tract leaks.
20430849 - Emergent self-expanding stent placement for acute intracranial or extracranial internal...
16227309 - Endovascular stent-graft placement in aortic dissection: a meta-analysis.
23997129 - The influence of comorbidity scores on re-operations following primary total hip replac...
8346749 - The dacron ligament prosthesis in anterior cruciate ligament reconstruction. a four-yea...
9917709 - Femoral head osteonecrosis after bone marrow transplantation.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Meta-Analysis; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  18     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-07-01     Completed Date:  2004-12-03     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  211-7     Citation Subset:  IM    
Affiliation:
Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan. hashiguchim@pharm.kitasato-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aspirin / administration & dosage,  adverse effects,  therapeutic use
Coronary Restenosis / complications
Coronary Stenosis / diagnosis,  therapy
Coronary Vessels / surgery
Data Collection / methods
Data Interpretation, Statistical
Death
Documentation / classification,  standards
Drug Administration Schedule*
Drug Therapy, Combination
Evaluation Studies as Topic
Humans
Japan
Medical Records / classification,  standards
Myocardial Infarction / complications
Odds Ratio
Stents / adverse effects,  utilization
Surgical Procedures, Elective / adverse effects,  methods*
Tetrazoles / administration & dosage,  adverse effects,  therapeutic use*
Ticlopidine / administration & dosage,  adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Tetrazoles; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients wi...
Next Document:  Methods of assessing the functional status of patients with left ventricular systolic dysfunction in...